All In Biotech

Drug Trial Radar · NCT05039840

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 109 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

109

Actual

Start

Nov 10, 2021

Primary completion

Sep 4, 2026

Study completion Nov 24, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • SAR441344 IVDrug

    Pharmaceutical form: solution Route of administration: Intravenous infusion

  • SAR441344 SCDrug

    Pharmaceutical form: solution Route of administration: subcutaneous injection

  • Placebo IVDrug

    Pharmaceutical form: solution Route of administration: Intravenous infusion

  • Placebo SCDrug

    Pharmaceutical form: solution Route of administration: subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24.Time frame: At Week 24

Locations

73 sites in 16 countries. Site status is shown where the registry gives one.

  • Accel Research Sites Network - Birmingham- Site Number : 8400003

    Vestavia Hills, Alabama

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026

    Chandler, Arizona

  • Arizona Arthritis & Rheumatology Associates - South Vineyard Avenue- Site Number : 8400022

    Mesa, Arizona

  • Arizona Arthritis & Rheumatology Research - Sun City- Site Number : 8400027

    Sun City, Arizona

  • AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast- Site Number : 8400023

    Tucson, Arizona

  • Saint John's Physician Partners- Site Number : 8400015

    Santa Monica, California

  • Millennium Clinical Trials - Simi Valley- Site Number : 8400004

    Simi Valley, California

  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400002

    DeBary, Florida

  • Vitalia Medical Research - Margate- Site Number : 8400039

    Margate, Florida

  • Innovia Research Center- Site Number : 8400037

    Miramar, Florida

  • Integral Rheumatology and Immunology Specialists- Site Number : 8400014

    Plantation, Florida

  • Infigo Clinical Research- Site Number : 8400016

    Sanford, Florida

  • Inspire Santa Fe Medical Group- Site Number : 8400019

    Santa Fe, New Mexico

  • Columbia University Irving Medical Center- Site Number : 8400009

    New York, New York

  • RAO - Rheumatology Associates of Oklahoma- Site Number : 8400013

    Oklahoma City, Oklahoma

  • Private Practice - Dr. Ramesh C. Gupta I- Site Number : 8400008

    Memphis, Tennessee

  • Tekton Research - West Gate- Site Number : 8400001

    Austin, Texas

  • Precision Comprehensive Clinical Research Solutions - Colleyville- Site Number : 8400017

    Colleyville, Texas

  • Lone Start Arthritis & Rheumatology Associates- Site Number : 8400025

    Fort Worth, Texas

  • Prolato Clinical Research Center- Site Number : 8400005

    Houston, Texas

  • AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400024

    Irving, Texas

  • West Texas Clinical Research- Site Number : 8400018

    Lubbock, Texas

  • Investigational Site Number : 0320006

    Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    Buenos Aires, Argentina

  • Investigational Site Number : 0320008

    Berazategui, Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    San Miguel de Tucumán, Tucumán Province, Argentina

  • IBCC - Núcleo de Pesquisa e Ensino- Site Number : 0760007

    São Paulo, Brazil

  • Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760004

    São Paulo, Brazil

  • Centro de Estudos em Terapias Inovadoras- Site Number : 0760002

    Curitiba, Paraná, Brazil

  • LMK Servicos Medicos- Site Number : 0760001

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760006

    São José do Rio Preto, São Paulo, Brazil

  • Investigational Site Number : 1520002

    Osorno, Los Lagos Region, Chile

  • Investigational Site Number : 1520003

    Talca, Maule Region, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 2680005

    Tbilisi, Georgia

  • Investigational Site Number : 2680004

    Tbilisi, Georgia

  • Investigational Site Number : 2680001

    Tbilisi, Georgia

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.